1. Akin C., Metcalfe D.: The biology of Kit in disease and the application of pharmacogenetics. J. Allergy Clin. Immunol. 2004, 114, 1, 13-19.
2. Baba Y., Nishida K., Fujii Y., Hirano T., Hikida M., Kurosaki T.: Essential function for the calcium sensor STIM1 in mast cell activation and anaphylactic responses. Nat. Immunol. 2008, 9,1,81-88.
3. Bernstein IL., Li JT., Bernstein DI., Hamilton R., Spector SL., Tan R., Golden DB., Khan DA., Nicklas RA., Portnoy JM., Blessing-Moore J., Cox L., Lang DM., Oppenheimer J., Randolph CC., Schuller DE., Tilles SA., Wallace DV., Levetin E., Weber R.: American Academy of Allergy, Asthma and Immunol-ogy; American College of Allergy, Asthma and Immunology. Allergy diagnos-tic testing: an updated pracdiagnos-tice parameter. Ann. Allergy Asthma Immunol.
2008,100,3 Suppl.3,1-148.
4. Biedermann T., Ruëff F., Sander CA., Przybilla B.: Mastocytosis associated with severe wasp sting anaphylaxis detected by elevated serum mast cell tryp-tase levels. Br. J. Dermatol. 1999,141,6,1110-1112.
5. Bilò MB., Brianzoni F., Cinti B., Napoli G., Bonifazi F. The dilemma of the negative skin test reactors with a history of venom anaphylaxis: will this always be the case? Eur. Ann. Allergy Clin. Immunol. 2005,37,9,341-342.
6. Biló BM., Rueff F., Mosbech H., Bonifazi F., Oude-Elberink JN.; the EAACI Interest Group on Insect Venom Hypersensitivity*. Diagnosis of Hymenoptera venom allergy. Allergy. 2005,60,11,1339-1349.
7. Birnbaum J., Ramadour M., Magnan A., Vervloet D.: Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin. Exp.
Allergy. 2003,33,1,58-64.
8. Bonadonna P., Perbellini O., Passalacqua G., Caruso B., Colarossi S., Dal Fior D., Castellani L., Bonetto C., Frattini F., Dama A., Martinelli G., Chilosi M., Senna G., Pizzolo G., Zanotti R.: Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J.
Allergy Clin. Immunol. 2009,123,3,680-686.
9. Bonadonna P., Zanotti R., Caruso B., Castellani L., Perbellini O., Colarossi S., Chilosi M., Dama A., Schiappoli M., Pizzolo G., Senna G., Passalacqua G.: Al-lergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J. Allergy Clin. Immunol.
2008,121,1,256-257.
10. Bonifazi F., Jutel M., Biló BM., Birnbaum J., Muller U.; EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005,60,12,1459-1470.
11. Brehler R., Wolf H., Kütting B., Schnitker J., Luger T. Safety of a two-day ul-trarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. J Allergy Clin Im-munol. 2000,105,6 Pt 1,1231-1235.
12. Brockow K., Jofer C., Behrendt H., Ring J.: Anaphylaxis in patients with mas-tocytosis: a study on history, clinical features and risk factors in 120 patients.
Allergy.2008,63,2,226-232.
13. Brożek JL., Akl EA., Alonso-Coello P., Lang D., Jaeschke R., Williams JW., Phillips B., Horvath AR., Bousquet J., Guyatt GH., Schünemann HJ.; GRADE Working Group. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Allergy. 2009,64,8,1109-1116.
14. Carmona-Saez P., Chagoyen M., Tirado F., Carazo JM., Pascual-Montano A.
GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 2007,8,1,R3.
15. Carter MC., Robyn JA., Bressler PB., Walker JC., Shapiro GG., Metcalfe DD.:
Omalizumab for the treatment of unprovoked anaphylaxis in patients with sys-temic mastocytosis. J. Allergy Clin. Immunol. 2007,119,6,1550-1551.
16. Charpin D., Birnbaum J., Vervloet D.: Epidemiology of hymenoptera allergy.
Clin. Exp. Allergy. 1994,24,11,1010-1015.
17. Crijns AP., Fehrmann RS., de Jong S., Gerbens F., Meersma GJ., Klip HG., Hollema H., Hofstra RM., te Meerman GJ., de Vries EG., van der Zee AG. Sur-vival-related profile, pathways, and transcription factors in ovarian cancer.
PLoS Med. 2009,6,2,e24.
18. Daley T., Metcalfe D., Akin C.: Association of the Q576R polymorphism in the interleukin-4 receptor alpha chain with indolent mastocytosis limited to the skin.
Blood 2001, 98,3:880-882.
19. D'ambrosio C., Akin C., Wu Y., Magnusson MK., Metcalfe DD. Gene expres-sion analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers. J. Allergy Clin. Immunol. 2003,112,6,1162-1170.
20. Fricker M., Helbling A., Schwartz L., Müller U.: Hymenoptera sting anaphy-laxis and urticaria pigmentosa: clinical findings and results of venom immuno-therapy in ten patients. J. Allergy Clin. Immunol. 1997,100,1,11-15.
21. González de Olano D., Alvarez-Twose I., Esteban-López MI., Sánchez-Muñoz L., de Durana MD., Vega A. García-Montero A., González-Mancebo E., Belver T., Herrero-Gil MD., Fernández-Rivas M., Orfao A., de la Hoz B., Castells MC., Escribano L. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphy-laxis. J. Allergy Clin. Immunol. 2008,121,2,519-526.
22. Dubois AE.: Mastocytosis and Hymenoptera allergy. Curr. Opin. Allergy Clin.
Immunol. 2004,4,4,291-295.
23. Dugas-Breit S., Przybilla B., Schöpf P., Ruëff F.: Possible circadian variation of serum mast cell tryptase concentration. Allergy. 2005,60,5,689-692.
24. Eberlein-König B., Varga R., Mempel M., Darsow U., Behrendt H., Ring J.:
Comparison of basophil activation tests using CD63 or CD203c expression in patients with insect venom allergy. Allergy. 2006,61,9,1084-5.
25. Engler RJ., Davis WS.: Rush Hymenoptera venom immunotherapy: successful treatment in a patient with systemic mast cell disease. J. Allergy Clin. Immunol.
1994,94,3 Pt 1,556-559.
26. Fehrmann RS., de Jonge HJ., Ter Elst A., de Vries A., Crijns AG., Weidenaar AC., Gerbens F., de Jong S., van der Zee AG., de Vries EG., Kamps WA., Hof-stra RM., Te Meerman GJ., de Bont ES. A new perspective on transcriptional system regulation (TSR): towards TSR profiling. PLoS One. 2008,3,2,e1656.
27. Fine J. Mastocytosis. Int. J. Dermatol. 1980,19,3,117-123.
28. Finegold I. Issues in stinging insect allergy immunotherapy: a review. Curr.
Opin. Allergy Clin. Immunol. 2008,8,4,343-347.
29. Florian S., Krauth MT., Simonitsch-Klupp I., Sperr WR., Fritsche-Polanz R., Sonneck K., Födinger M., Agis H., Böhm A., Wimazal F., Horny HP., Valent P.: Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent anaphylactoid episodes. Int. Arch. Allergy Immunol.
2005,136,3,273-280.
30. Franken HH., Dubois AE., Minkema HJ., van der Heide S., de Monchy JG.:
Lack of reproducibility of a single negative sting challenge response in the as-sessment of anaphylactic risk in patients with suspected yellow jacket hypersen-sitivity. J. Allergy Clin. Immunol. 1994,93,2:431-436.
31. Garcia-Montero AC., Jara-Acevedo M., Teodosio C., Sanchez ML., Nunez R., Prados A., Aldanondo I., Sanchez L., Dominguez M., Botana LM., Sanchez-Jimenez F., Sotlar K., Almeida J., Escribano L., Orfao A. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006,108,7,2366-2372.
32. Golden DB. Insect sting anaphylaxis. Immunol. Allergy. Clin. North. Am.
2007,27,2,261-272.
33. Golden D., Kwiterovich K., Kagey-Sobotka A., Lichtenstein L.: Discontinuing venom immunotherapy: Extended observations. J. Allergy Clin. Immunol.
1998,101,3,298-305.
34. Golden DB., Marsh DG., Freidhoff LR., Kwiterovich KA., Addison B., Kagey-Sobotka A., Lichtenstein LM.: Natural history of Hymenoptera venom sensitiv-ity in adults. J. Allergy Clin. Immunol. 1997,100,P Pt 1,760-766.
35. Golkar L., Bernhard J.: Mastocytosis. Lancet.1997,349,9062,1379-1385.
36. Gonera R., Oranje W., Wolffenbuttel B.: Shock of unknown origin-think of mastocytosis! Neth. J. Med.1997;50,4,165-169.
37. Gorska L., Chelminska M., Kuziemski K., Skrzypski M., Niedoszytko M., Damps-Konstanska I. Szymanowska A., Siemińska A., Wajda B., Drozdowska A., Jutel M., Jassem E.: Analysis of safety, risk factors and pretreatment meth-ods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immu-nol. 2008,147,3,241-245.
38. Guyatt GH., Oxman AD., Kunz R., Falck-Ytter Y., Vist GE., Liberati A., Schünemann HJ.;GRADE Working Group. Going from evidence to recommen-dations. BMJ. 2008,336,7652,1049-1051.
39. Haeberli G., Brönnimann M., Hunziker T., Müller U. Elevated basal serum tryp-tase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin. Exp. Allergy.
2003,33,9,1216-1220.
40. Hermann K., Donhauser S., Ring J.: Angiotensin in Human Leukocytes of Pa-tients with Insect Venom Anaphylaxis and Healthy Volunteers. Int. Arch. Al-lergy Immunol.1995,107,1-3,385-86.
41. Hermann K., Ring J.: Association between the renin angiotensis system and anaphylaxis. Adv. Exp. Med. Biol. 1995, 377, 299-309.
42. Hermann J., Ring J.: Human leukocytes contain angiotensin I, angiotensin II and angiotensin metabolites. Int. Arch. Allergy Immunol. 1994,103,2,152-59.
43. Hermann K., Ring J.: The renin-angiotensin system in patients with treated ana-phylactic reactions during Hymenoptera venom hyposensitization and sting challenge. Int, Arch, Allergy Immunol. 1997,112,3,251-256.
44. Hermann K., Ring J.: The renin angiotensin system and hymenoptera venom anaphylaxis. Clin. Exp. Allergy. 1993,23,9,762-769.
45. Holla L., Vask A., Znojil V., Sisková L., Vácha J.: Association of 3 gene poly-morphisms with atopic diseases. J. Allergy Clin. Immunol. 1999,103,4,702-8.
46. Ippoliti F., De Santis W., Volterrani A., Lenti L., Canitano N., Lucarelli S., Frediani T.: Immunomodulation during sublingual therapy in allergic children.
Pediatr. Allergy Immunol. 2003,14,3,216-221.
47. Jassem E., Niedoszytko M. Mastocytoza rozpoznanie i leczenie. W Fal A.(red):
Alergia, choroby alergiczne, astma. T.2. Medycyna Praktyczna 2011 (w druku)
48. Jutel M., Akdis M., Blaser K., Akdis CA.: Mechanisms of allergen specific im-munotherapy-T-cell tolerance and more. Allergy. 2006,61,7,796-807.
49. Kanehisa M., Araki M., Goto S., Hattori M., Hirakawa M., Itoh M., Kawashima S., Okuda S., Tokimatsu T., Yamanishi Y.: KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008,36,480-484.
50. Kanehisa M., Goto S., Hattori M., Aoki-Kinoshita KF., Itoh M., Kawashima S., Katayama T., Araki M., Hirakawa M.: From genomics to chemical genomics:
new developments in KEGG. Nucleic Acids Res. 2006,34,354-357.
51. Kawabata Y., Yan T., Yokochi T, Matsushita M, Fujita T., Shibazaki M., No-ikura T., Endo TY., Takada H.:. Complement system is involved in anaphylac-toid rections induced by lipopolisacharides in muramyldipeptide-treated mice.
Shock 2000,14,5,572-577.
52. Kazmierska J., Malicki J. Application of the Naïve Bayesian Classifier to opti-mize treatment decisions. Radiother. Oncol. 2008,86,2,211-216.
53. Kazani S., Wechsler ME., Israel E. The role of pharmacogenomics in improving the management of asthma. J Allergy Clin Immunol. 2010,125,2,295-302.
54. Kim JJ., Kim HJ., Lee IK., Chung HT., Lee JH. Association between polymor-phisms of the angiotensin-converting enzyme and angiotensinogen genes and allergic rhinitis in a Korean population. Ann. Otol. Rhinol. Laryngol.
2004,113,4,297-302.
55. Konno S., Hizawa N., Nishimura M., Huang SK.: Osteopontin: a potential bio-marker for successful bee venom immunotherapy and a potential molecule for inhibiting IgE-mediated allergic responses. Allergol. Int. 2006,55,4,355-359.
56. Kononenko I.: Machine learning for medical diagnosis: history, state of the art and perspective. Artif. Intell. Med. 2001,23,1,89-109.
57. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy. 2008,63,3,376-378.
58. Kontou-Fili K. Patients with negative skin tests. Curr. Opin. Allergy Clin. Im-munol. 2002,2,4,353-357.
59. Kors JW., van Doormaal JJ., de Monchy JG.: Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis. J. Intern.
Med. 1993,233,3,255-258.
60. Kränke B., Sturm G., Aberer W.: Negative venom skin test results and mastocy-tosis. J. Allergy Clin. Immunol. 2004,113,1,180-181.
61. Kucera P., Cvackova M., Hulikova K., Juzova O., Pachl J.: Basophil activation can predict clinical sensitivity in patients after venom immunotherapy. J. Inves-tig. Allergol. Clin. Immunol. 2010,20,2,110-116.
62. Ludolph-Hauser D., Ruëff F., Fries C., Schöpf P., Przybilla B. Constitutively raised serum concentrations of mast-cell tryptase and severe anaphylactic reac-tions to Hymenoptera stings. Lancet. 2001,357,9253,361-362.
63. Mauss V. Potential effects of global warming on hymenoptera biology and the risk of stings. Allergy 2009,64,579.
64. Meeker ND., Yang JJ., Schiffman JD.: Pharmacogenomics of pediatric acute lymphoblastic leukemia. Expert Opin. Pharmacother. 2010,11,10,1621-1632.
65. Mosbech H., Müller U.: Side effects of insect venom immunotherapy: results from an EAACI multicenter study. Allergy 2000,55,11,1005-1010.
66. Mueller UR.: Cardiovascular disease and anaphylaxis. Curr. Opin. Allergy Clin.
Immunol. 2007,7,4,337-341.
67. Mueller HL. Diagnosis and treatment of insect sensitivity. J. Asthma Res.1966,3,4,331-333.
68. Müller UR. New developments in the diagnosis and treatment of hymenoptera venom allergy. Int Arch Allergy Immunol. 2001,124,4:447-453.
69. Müller U., Helbling A., Berchtold E.: Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J. Allergy Clin. Immunol. 1992,89,2,529-535.
70. Müller UR., Horat W., Wüthrich B., Conroy M., Reisman RE.: Anaphylaxis after Hymenoptera stings in three patients with urticaria pigmentosa. J. Allergy Clin. Immunol. 1983,72,6,685-689.
71. Nedoszytko B., Niedoszytko M., Lange M., van Doormaal J., Gleń J., Zabłotna M., Renke J., Vales A., Buljubasic F., Jassem E., Roszkiewicz J., Valent P.:
Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis. Allergy. 2009,64,2,287-294.
72. Niedoszytko M., Lange M., Chelminska M., Jaśkiewicz K., Piskosz A., Wasag B., Lewandowski K., Mital A., Renke J., Gruchała-Niedoszytko M., Woźniak M., Babińska A., Jassem E.: [Systemic mastocytosis] Pneumonol. Alergol. Pol.
2005,73,3,239-244.
73. Nogales-Cadenas R., Carmona-Saez P., Vazquez M., Vicente C., Yang X., Ti-rado F., Carazo JM., Pascual-Montano A.:GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information.
Nucleic Acids Res. 2009,37,317-322.
74. Oude Elberink JN., de Monchy JG., Kors JW., van Doormaal JJ., Dubois AE.:
Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J. Allergy Clin. Immunol. 1997,99,1 Pt 1,153-154.
75. Peavy R., Metcalfe D. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol. 2008,8,4,310-315.
76. Piekutowska-Abramczuk D., Olsen RK., Wierzba J., Popowska E., Jurkiewicz D., Ciara E., Ołtarzewski M., Gradowska W., Sykut-Cegielska J., Krajewska-Walasek M., Andresen BS., Gregersen N., Pronicka E. A comprehensive HADHA c.1528G>C frequency study reveals high prevalence of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency in Poland. J. Inherit. Metab. Dis.
2010 Sep 3. [Epub ahead of print]
77. Price LA., Safko M.: Bee venom allergy in a patient with urticaria pigmentosa.
J. Allergy Clin. Immunol. 1987,79,2,407-409.
78. Pumphrey R., Roberts I.: Postmortem findings after fatal anaphylactic reaction.
J. Clin. Pathol. 2000,53,4,273-276.
79. Reimers A., Müller U.: Fatal outcome of a Vespula sting in a patient with mas-tocytosis after specific immunotherapy with honey bee venom. Allergy Clin.
Immunol. Int. J. WAO Org. 2005,17,68-70.
80. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., Soubrier F.: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest.
1990,86,4,1343-46.
81. Roepman P., Jassem J., Smit EF., Muley T., Niklinski J., van de Velde T., Wit-teveen AT., Rzyman W., Floore A., Burgers S., Giaccone G., Meister M., Die-nemann H., Skrzypski M., Kozlowski M., Mooi WJ., van Zandwijk N.: An im-mune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin. Cancer Res. 2009,15,1,284-290.
82. Ruëff F, Bilò MB, Jutel M, Mosbech H, Müller U, Przybilla B: Sublingual im-munotherapy with venom is not recommended for patients with Hymenoptera venom allergy. J. Allergy Clin. Immunol. 2009,123,1,272-273.
83. Ruëff F., Przybilla B., Biló MB., Müller U., Scheipl F., Aberer W., Birnbaum J., Bodzenta-Lukaszyk A., Bonifazi F., Bucher C., Campi P., Darsow U., Egger C., Haeberli G., Hawranek T., Körner M., Kucharewicz I., Küchenhoff H., Lang R., Quercia O., Reider N., Severino M., Sticherling M., Sturm GJ., Wüthrich B.:
Predictors of severe systemic anaphylactic reactions in patients with Hymenop-tera venom allergy: importance of baseline serum tryptase-a study of the Euro-pean Academy of Allergology and Clinical Immunology Interest Group on In-sect Venom Hypersensitivity. J. Allergy Clin. Immunol. 2009,124,5,1047-1054.
84. Ruëff F., Przybilla B., Biló MB., Müller U., Scheipl F., Aberer W., Birnbaum J., Bodzenta-Lukaszyk A., Bonifazi F., Bucher C., Campi P., Darsow U., Egger C., Haeberli G., Hawranek T., Kucharewicz I., Küchenhoff H., Lang R., Quercia O., Reider N., Severino M., Sticherling M., Sturm GJ., Wüthrich B.: European Academy of Allergy and Clinical Immunology Interest Group. Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J. Allergy Clin. Im-munol. 2010;126,1,105-111.
85. Rernick H., Przybilla B., Rueff F.: Venom immunotherapy (VIT) in patients with systemic mastocytosis (SM) and hymenoptera anaphylaxis (HVA): safety and efficacy of different maintenance doeses. Abstract no 936, AAAAI 2009 annual meeting.
86. Ruëff F., Placzek M., Przybilla B.: Mastocytosis and Hymenoptera venom al-lergy. Curr Opin Allergy Clin. Immunol. 2006,6,4,284-288.
87. Ruëff F., Wenderoth A., Przybilla B.: Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J. Allergy Clin. Immunol. 2001,108,6,1027-1032.
88. Rush JW., Aultman CD.: Vascular biology of angiotensin and the impact of physical activity. Appl. Physiol. Nutr. Metab. 2008,33,1,162-72.
89. Sharabi AB., Aldrich M., Sosic D., Olson EN., Friedman AD., Lee SH., Chen SY.: Twist-2 controls myeloid lineage development and function. PLoS Biol.
2008,6,12,e316.
90. Soriano Gomis V., Gonzalez Delgado P., Niveiro Hernandez E.: Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immuno-therapy. J. Investig. Allergol. Clin. Immunol. 2008,18,3,225-256.
91. Stumpf JL., Shehab N., Patel AC.: Safety of Angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann. Pharmacother.
2006,40,4,699-703.
92. Sturm G., Kränke B., Rudolph C., Aberer W.: Rush Hymenoptera venom im-munotherapy: a safe and practical protocol for high-risk patients. J. Allergy Clin. Immunol. 2002,110,6,928-933.
93. Szymański W., Bodzenta-Łukaszyk A. Obraz kliniczny alergii na jady owadów.
W red. Nitter-Marszalska M.: Alergia na jad owadów błonkoskrzydłych. Medi-ton. Łódź 2003.
94. Valent P., Akin C., Escribano L., Födinger M., Hartmann K., Brockow K., Ca-stells M., Sperr WR., Kluin-Nelemans HC., Hamdy NA., Lortholary O., Robyn J., van Doormaal J., Sotlar K., Hauswirth AW., Arock M., Hermine O., Hell-mann A., Triggiani M., Niedoszytko M., Schwartz LB., Orfao A., Horny HP., Metcalfe DD.: Standards and standardization in mastocytosis: consensus state-ments on diagnostics, treatment recommendations and response criteria. Eur. J.
Clin. Invest. 2007, 37, 6,435-453.
95. Valent P., Horny HP., Escribano L., Longley BJ., Li CY., Schwartz LB., Ma-rone G., Nuñez R., Akin C., Sotlar K., Sperr WR., Wolff K., Brunning RD., Parwaresch RM., Austen KF., Lennert K., Metcalfe DD., Vardiman JW., Ben-nett JM.: Diagnostic criteria and classification of mastocytosis: a consensus pro-posal. Leuk. Res. 2001,25,7,603-625.
96. Valent P., Sperr W., Schwartz L., Horny H.: Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J. Allergy Clin. Immunol.2004,114,1,3-11.
97. van 't Veer LJ., Dai H., van de Vijver MJ., He YD., Hart AA., Mao M., Peterse HL., van der Kooy K., Marton MJ., Witteveen AT., Schreiber GJ., Kerkhoven RM., Roberts C., Linsley PS., Bernards R., Friend SH. Gene expression profil-ing predicts clinical outcome of breast cancer. Nature. 2002,415,6871,530-536.
98. Vennekens R., Olausson J., Meissner M., Bloch W., Mathar I., Philipp SE., Schmitz F., Weissgerber P., Nilius B., Flockerzi V., Freichel M.: Increased IgE dependent mast cell activation and anaphylactic responses in mice lacking the calcium activated nonselective cation channel TRPM4. Nat. Immunol.
2007,8,3,312-320.
99. Volcheck G., Butterfield J., Yunginger J., Klee G.: Elevated serum levels of calcitonin gene-related peptide in Hymenoptera venom anaphylaxis. J. Allergy Clin. Immunol. 1998,102,1,149-151.
100. Wagner N., Fritze D., Przybilla B., Hagedorn M., Ruëff F.: Fatal anaphylactic sting reaction in a patient with mastocytosis. Int. Arch. Allergy Immunol.
2008,146,2,162-163.
101. Wenzel J., Meissner-Kraemer M., Bauer R., Bieber T., Gerdsen R.: Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy. 2003,58,11,1176-1179.
102. Zimmerli SC., Hauser C. Langerhans cells and lymph node dendritic cells ex-press the tight junction component claudin-1. J. Invest. Dermatol.
2007,127,10,2381-2390.